Arthneeti
IR

Indoco Remedies

Q4 FY26Pharmaceuticals & Biotechnology

Indoco Remedies Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹226
Market cap₹2.0K Cr
Updated23 Aug 2026
Read4 min read

The short version

India Business: Expected to grow in line with IPM; focus on new product launches (e.g., Drotitec M, Vepazil, Cyclopam AC suspension) contributing around INR 20 crore annually, with new launches performing well. Europe business and base contract manufacturing expected to grow with better margins due to completed MMP scale-ups.

From Indoco Remedies's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • India Business: Expected to grow in line with IPM; focus on new product launches (e.g., Drotitec M, Vepazil, Cyclopam AC suspension) contributing around INR 20 crore annually, with new launches performing well.
  • Regulated Markets (Europe & US): Continued growth anticipated with better margins, especially from contract manufacturing; expansion into liquid oral products planned for FY '27-'28.
  • Emerging Markets: High confidence for growth in next 2-3 years driven by strong portfolio and active field force in Africa regions.
  • Warren Remedies (India OTC): Business grown from INR 90-94 crore to INR 120-130 crore; expecting further growth with key brands and new product launches.

2 more points management made on revenue & sales performance

Profitability & Margins

See what Indoco Remedies said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • No major CAPEX is planned for the next 2 years as per Pramod Ghorpade's statement.
  • Current focus is on tight control of CAPEX and reducing operating expenses.
  • API plant has ongoing validations and capital expenditure already done, but no new significant investments are planned.
  • Efforts are underway to expedite USFDA approvals to speed up sales from the API plant.

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Indoco Remedies said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly provide details on the current or expected order book or pending orders. However, relevant insights include: - Europe business, especially base contract manufacturing, is expected to continue growing with better margins. - U.S. market growth driven by sterile products and a substantial portfolio of solid oral products. - Plans to launch liquid orals in Europe and U.S., expected to contribute to growth. - Emerging market business (Eastern Africa & French West Africa) has a strong product portfolio and field force, with confidence for growth over the next 2-3 years. - Warren Remedies has started exports (to South Africa) with initial small orders and is seeking further opportunities.

2 more points management made on order book & pipeline

Indoco Remedies — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹476 Cr, net loss ₹24 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Indoco Remedies's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Aptus Pharma Ltd (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

  • Morepen Laboratories Ltd (Q4 FY26)

    472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…

  • Anuh Pharma Ltd (Q4 FY26)

    202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…

  • Themis Medicare Ltd (Q4 FY26)

    Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Indoco Remedies Q4 FY26 results?

India Business: Expected to grow in line with IPM; focus on new product launches (e.g., Drotitec M, Vepazil, Cyclopam AC suspension) contributing around INR 20 crore annually, with new launches performing well. Europe business and base contract manufacturing expected to grow with better margins due to completed MMP scale-ups.

What is Indoco Remedies share price analysis?

Indoco Remedies currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹2,026 Cr. Investors should review the full earnings analysis for detailed insights.

Is Indoco Remedies planning capital expenditure?

No major CAPEX is planned for the next 2 years as per Pramod Ghorpade's statement.

Keep Indoco Remedies on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.